Studies of Erythrocyte Membrane Structure

红细胞膜结构的研究

基本信息

  • 批准号:
    7798065
  • 负责人:
  • 金额:
    $ 45.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1977
  • 资助国家:
    美国
  • 起止时间:
    1977-07-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The human erythrocyte membrane (RBCM) is the most thoroughly studied plasma membrane, not only because it serves as an accessible model of other human membranes, but also because inherited and acquired defects in its components lead to serious pathologies. Despite this scrutiny, fundamental aspects of the structure and function of the RBCM remain poorly understood. In Aim 1, we will characterize the structure and function of a newly discovered bridge (band 3 to 2-adducin to spectrin) that links the lipid bilayer to the spectrin-actin skeleton. We have recently demonstrated that ~1/3 of the band 3 population is anchored to the spectrin/actin junctional complex via this bridge and that rupture of the bridge leads to membrane fragmentation. To evaluate the significance of the bridge in vivo, we will map the binding site of adducin on band 3, identify mutations in band 3 that prevent adducin binding, generate a mouse containing the mutant band 3, and evaluate the morphological and mechanical properties of the mutant erythrocytes. Included as a major component of this aim is the characterization of a method to image the diffusion of single band 3 molecules in intact erythrocytes as a tool to sensitively monitor perturbations of RBCM structure. The membrane-spanning domain of band 3 (msdb3) not only mediates anion transport across the membrane, but also organizes a complex of membrane-spanning proteins, including glycophorin A, CD47, Rh proteins, aquaporin, and several transporters. In order to understand the function of msdb3 at a molecular level, we will solve its crystal structure at high resolution (This will be the first structure of any member of solute carrier class IV). We currently have crystals that diffract to <6E, and although we could solve a 6E structure now, we are confident that we can generate much higher resolution crystals using the novel strategies outlined in Aim 2. Strong evidence suggests that 1) red cell metabolism, 2) membrane structural properties, and 3) ion transport are regulated by O2. Because deoxyhemoglobin (but not oxyHb) binds with high affinity to band 3, and since band 3 associates with proteins responsible for each of the above properties, we hypothesize that the reversible association of band 3 with deoxyHb constitutes the "molecular switch" through which red cell oxygenation regulates membrane properties. In Aim 3, we will test this hypothesis using recently discovered band 3 mutations that either: i) eliminate all affinity for deoxyHb, or ii) enhance the affinity of deoxyHb for band 3 so significantly that deoxyHb can neither release its O2 nor dissociate from band 3, even at saturating O2. We propose to generate knock-in mice that express these two mutant band 3s, and use the mice to determine if the above O2- regulated properties are permanently "switched on" or permanently "switched off", as predicted. PUBLIC HEALTH RELEVANCE: The red blood cell performs a variety of functions critical to our survival, including transport of oxygen from the lungs to the tissues and carbon dioxide from the tissues to the lungs, delivery of nitric oxide to facilitate blood flow, participation in blood clotting to facilitate wound healing, and regulation of a number of other reactions that occur in the blood. Our research seeks to understand the molecular basis of each of these important functions, and where possible, to define clinical interventions that might enable treatment of conditions where the above processes malfunction.
描述(由申请人提供):人红细胞膜(RBCM)是研究最彻底的质膜,不仅因为它是其他人体膜的可访问模型,还因为其组分中的遗传性和获得性缺陷导致严重的病理学。尽管进行了这种审查,但对管理区域局的结构和职能的基本方面仍然知之甚少。在目标1中,我们将描述一个新发现的桥梁(带3到2-adducin血影蛋白)的结构和功能,连接脂质双层的血影蛋白肌动蛋白骨架。我们最近已经证明,约1/3的带3人口通过这座桥锚定到血影蛋白/肌动蛋白连接复合物,桥的断裂导致膜断裂。为了评估体内桥的意义,我们将绘制带3上内收蛋白的结合位点,鉴定带3中阻止内收蛋白结合的突变,产生含有突变带3的小鼠,并评估突变红细胞的形态学和机械特性。包括作为一个主要组成部分,这一目标是表征的方法,以图像的扩散的单一带3分子在完整的红细胞作为一种工具,灵敏地监测扰动的红细胞膜结构。带3的跨膜结构域(msdb 3)不仅介导阴离子跨膜转运,而且组织跨膜蛋白的复合物,包括血型糖蛋白A、CD 47、Rh蛋白、水通道蛋白和几种转运蛋白。为了在分子水平上理解msdb 3的功能,我们将以高分辨率解析其晶体结构(这将是溶质载体IV类任何成员的第一个结构)。我们目前有晶体的分辨率<6 E,虽然我们现在可以解决6 E结构,但我们相信我们可以使用目标2中概述的新策略生成更高分辨率的晶体。强有力的证据表明,1)红细胞代谢,2)膜结构特性,3)离子转运受O2调节。由于脱氧血红蛋白(但不是oxyHb)结合带3具有高亲和力,并由于带3与负责上述每一个属性的蛋白质,我们假设,可逆的协会带3与脱氧血红蛋白构成的“分子开关”,通过红细胞氧合调节膜的性能。在目标3中,我们将使用最近发现的带3突变来检验这一假设,所述带3突变:i)消除对脱氧血红蛋白的所有亲和力,或ii)显著增强脱氧血红蛋白对带3的亲和力,使得脱氧血红蛋白既不能释放其O2也不能从带3解离,即使在饱和O2下。我们建议产生敲入小鼠表达这两个突变体带3,并使用小鼠来确定上述O2调节特性是否永久“打开”或永久“关闭”,如预测的那样。公共卫生关系:红细胞执行对我们的生存至关重要的各种功能,包括将氧气从肺输送到组织,将二氧化碳从组织输送到肺,输送一氧化氮以促进血液流动,参与血液凝固以促进伤口愈合,以及调节血液中发生的许多其他反应。我们的研究旨在了解这些重要功能的分子基础,并在可能的情况下,确定可能能够治疗上述过程发生故障的条件的临床干预措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHILIP Stewart LOW其他文献

PHILIP Stewart LOW的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHILIP Stewart LOW', 18)}}的其他基金

Project 2: Near-Infrared Targeted Tracers for Intraoperative Identification of NSCLC
项目2:用于术中识别NSCLC的近红外靶向示踪剂
  • 批准号:
    10647645
  • 财政年份:
    2022
  • 资助金额:
    $ 45.38万
  • 项目类别:
Project 2: Near-Infrared Targeted Tracers for Intraoperative Identification of NSCLC
项目2:用于术中识别NSCLC的近红外靶向示踪剂
  • 批准号:
    10333065
  • 财政年份:
    2022
  • 资助金额:
    $ 45.38万
  • 项目类别:
Near infrared intraoperative molecular imaging of lung adenocarcinoma
肺腺癌近红外术中分子影像
  • 批准号:
    9198209
  • 财政年份:
    2016
  • 资助金额:
    $ 45.38万
  • 项目类别:
Near infrared intraoperative molecular imaging of lung adenocarcinoma
肺腺癌近红外术中分子影像
  • 批准号:
    9030040
  • 财政年份:
    2016
  • 资助金额:
    $ 45.38万
  • 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
  • 批准号:
    6712779
  • 财政年份:
    2002
  • 资助金额:
    $ 45.38万
  • 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
  • 批准号:
    6622784
  • 财政年份:
    2002
  • 资助金额:
    $ 45.38万
  • 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
  • 批准号:
    6455374
  • 财政年份:
    2002
  • 资助金额:
    $ 45.38万
  • 项目类别:
1999 GORDON CONFERENCE ON THE RED CELL
1999 年戈登红细胞会议
  • 批准号:
    2807356
  • 财政年份:
    1999
  • 资助金额:
    $ 45.38万
  • 项目类别:
RED CELL TYROSINE KINASES AND REGULATION OF METABOLISM
红细胞酪氨酸激酶和代谢调节
  • 批准号:
    2180639
  • 财政年份:
    1988
  • 资助金额:
    $ 45.38万
  • 项目类别:
RED CELL TYROSINE KINASES AND REGULATION OF METABOLISM
红细胞酪氨酸激酶和代谢调节
  • 批准号:
    3298949
  • 财政年份:
    1988
  • 资助金额:
    $ 45.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了